Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study

British Journal of Cancer

Volumn 109, Issue 12, 2013, Pages 3057-3066

  Aparicio, T ^a   Svrcek, M ^b   Zaanan, A ^c,d   Beohou, E ^e   Laforest, A ^d   Afchain, P ^b   Mitry, Emmanuel ^f   Taieb, J ^c   Di Fiore, F ^g   Gornet, J M ^h   Thirot Bidault, A ⁱ   Sobhani, I ^j   Malka, D ^k   Lecomte, T ^l   Locher, C ^m   Bonnetain, F ^e   Laurent Puig, P ^d  

^a AVICENNE HOSPITAL   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d INSERM   (France)

^e UNIVERSITY HOSPITAL OF BESANÇON   (France)

^f INSTITUT CURIE   (France)

^g HÔPITAL CHARLES NICOLLE   (France)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ BICÊTRE HOSPITAL   (France)

^j HENRI MONDOR HOSPITAL   (France)

^k INSTITUT GUSTAVE ROUSSY   (France)

^l UNIVERSITY HOSPITAL OF TOURS   (France)

^m NONE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BETA CATENIN; BEVACIZUMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; MISMATCH REPAIR PROTEIN PMS2; OXALIPLATIN; PROTEIN MLH1; PROTEIN P53; VALINE;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CODON; COLORECTAL CANCER; CONTROLLED STUDY; CROHN DISEASE; DUODENUM; ENZYME DEFICIENCY; FEMALE; FOLLOW UP; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; ILEUM; IMMUNOHISTOCHEMISTRY; JEJUNUM; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR PROTEIN DEFICIENCY; MONOTHERAPY; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RARE DISEASE; SMALL BOWEL ADENOCARCINOMA; STOMACH CANCER;

ADENOCARCINOMA; ADULT; AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL NEOPLASMS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; PHENOTYPE; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84890439096     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.677     Document Type: Article

References (50)

1. Aparicio T, Manfredi S, Tougeron D, Bouche O, Pezet D, Mariette C, Coriat R, Zaanan A, Legoux JL, Afchain P (2013a) NADEGE prospective cohort: demographic data of 335 small bowel adenocarcinomas. Eur Cancer Congress Abstract no. 2466. Available at: http://eccamsterdam2013.ecco-org.eu/Scientific- Programme/Abstract-search.
2. Aparicio T, Schischmanoff O, Poupardin C, Soufir N, Angelakov C, Barrat C, Levy V, Choudat L, Cucherousset J, Boubaya M, Lagorce C, Guetz GD, Wind P, Benamouzig R (2013b) Deficient mismatch repair phenotype is a prognostic factor for colorectal cancer in elderly patients. Dig Liver Dis 45: 245-250.
3. Aparicio T, Zaanan A, Svrcek M, Laurent-Puig P, Carrere N, Manfredi S, Locher C, Afchain P (2013c) Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. Dig Liver Dis; e-pub ahead of print 21 June 2013; pii: S1590-8658(13)00184-9; doi:10.1016/j.dld.2013.04.013.
4. Arai M, Shimizu S, Imai Y, Nakatsuru Y, Oda H, Oohara T, Ishikawa T (1997) Mutations of the Ki-ras, p53 and APC genes in adenocarcinomas of the human small intestine. Int J Cancer 70: 390-395.
5. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697.
6. Behrens J (2005) The role of the Wnt signalling pathway in colorectal tumorigenesis. Biochem Soc Trans 33: 672-675.
7. Bellini MF, Cadamuro AC, Succi M, Proenca MA, Silva AE (2012) Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol 2012: 891961.
8. Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS (2009) Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 249: 63-71.
9. Blaker H, Helmchen B, Bonisch A, Aulmann S, Penzel R, Otto HF, Rieker RJ (2004) Mutational activation of the RAS-RAF-MAPK and theWnt pathway in small intestinal adenocarcinomas. Scand J Gastroenterol 39: 748-753.
10. Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M, Guimbaud R, Buecher B, Bignon YJ, Caron O, Colas C, Nogues C, Lejeune-Dumoulin S, Olivier-Faivre L, Polycarpe-Osaer F, Nguyen TD, Desseigne F, Saurin JC, Berthet P, Leroux D, Duffour J, Manouvrier S, Frebourg T, Sobol H, Lasset C, Bonaiti-Pellie C (2011) Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305: 2304-2310.
11. Brueckl WM, Heinze E, Milsmann C, Wein A, Koebnick C, Jung A, Croner RS, Brabletz T, Gunther K, Kirchner T, Hahn EG, Hohenberger W, Becker H, Reingruber B (2004) Prognostic significance of microsatellite instability in curatively resected adenocarcinoma of the small intestine. Cancer Lett 203: 181-190.
12. Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J (2004) Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 101: 518-526.
13. Faivre J, Trama A, De Angelis R, Elferink M, Siesling S, Audisio R, Bosset JF, Cervantes A, Lepage C (2012) Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-2002, Eur J Cancer 48: 1417-1424.
14. Fu T, Guzzetta AA, Jeschke J, Vatapalli R, Dave P, Hooker CM, Morgan R, Iacobuzio-Donahue CA, Liu B, Ahuja N (2012) KRAS G4A mutation favors poor tumor differentiation but may not be associated with prognosis in patients with curatively resected duodenal adenocarcinoma. Int J Cancer 132(11): 2502-2509.
15. Haan JC, Buffart TE, Eijk PP, van de Wiel MA, vanWieringenWN, Howdle PD, Mulder CJ, van de Velde CJ, Quirke P, Nagtegaal ID, van Grieken NC, Grabsch H, Meijer GA, Ylstra B (2012) Small bowel adenocarcinoma copy number profiles are more closely related to colorectal than to gastric cancers. Ann Oncol 23: 367-374.
16. Halfdanarson TR, McWilliams RR, Donohue JH, Quevedo JF (2010) A singleinstitution experience with 491 cases of small bowel adenocarcinoma. Am J Surg 199: 797-803.
17. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, Sotamaa K, Prior TW, Westman J, Panescu J, Fix D, Lockman J, Comeras I, de la CA (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352: 1851-1860.
18. Hao X, Tomlinson I, Ilyas M, Palazzo JP, Talbot IC (1997) Reciprocity between membranous and nuclear expression of beta-catenin in colorectal tumours. Virchows Arch 431: 167-172.
19. Howe JR, Karnell LH, Menck HR, Scott-Conner C (1999) The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995, Cancer 86: 2693-2706.
20. Ilyas M, Straub J, Tomlinson IP, Bodmer WF (1999) Genetic pathways in colorectal and other cancers. Eur J Cancer 35: 335-351.
21. Kim HS, Hong EK, Park SY, Kim WH, Lee HS (2003) Expression of beta-catenin and E-cadherin in the adenoma-carcinoma sequence of the stomach. Anticancer Res 23: 2863-2868.
22. Koinuma K, Shitoh K, Miyakura Y, Furukawa T, Yamashita Y, Ota J, Ohki R, Choi YL, Wada T, Konishi F, Nagai H, Mano H (2004) Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas. Int J Cancer 108: 237-242.
23. Kummar S, Ciesielski TE, Fogarasi MC (2002) Management of small bowel adenocarcinoma. Oncology (Williston Park) 16: 1364-1369.
24. Lee HJ, Lee OJ, Jang KT, Bae YK, Chung JY, Eom DW, Kim JM, Yu E, Hong SM (2013) Combined loss of E-cadherin and aberrant beta-catenin protein expression correlates with a poor prognosis for small intestinal adenocarcinomas. Am J Clin Pathol 139: 167-176.
25. Lepage C, Bouvier AM, Manfredi S, Dancourt V, Faivre J (2006) Incidence and management of primary malignant small bowel cancers: a welldefined French population study. Am J Gastroenterol 101: 2826-2832.
26. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379.
27. Muneyuki T, Watanabe M, Yamanaka M, Isaji S, Kawarada Y, Yatani R (2000) Combination analysis of genetic alterations and cell proliferation in small intestinal carcinomas. Dig Dis Sci 45: 2022-2028.
28. Murata M, Iwao K, Miyoshi Y, Nagasawa Y, Ohta T, Shibata K, Oda K, Wada H, Tominaga S, Matsuda Y, Ohsawa M, Nakamura Y, Shimano T (2000) Molecular and biological analysis of carcinoma of the small intestine: beta-catenin gene mutation by interstitial deletion involving exon 3 and replication error phenotype. Am J Gastroenterol 95: 1576-1580.
29. Neugut AI, Jacobson JS, Suh S, Mukherjee R, Arber N (1998) The epidemiology of cancer of the small bowel. Cancer Epidemiol Biomarkers Prev 7: 243-251.
30. Nicholl MB, Ahuja V, Conway WC, Vu VD, Sim MS, Singh G (2010) Small bowel adenocarcinoma: understaged and undertreated? Ann Surg Oncol 17: 2728-2732.
31. Olschwang S, Hamelin R, Laurent-Puig P, Thuille B, De Rycke Y, Li YJ, Muzeau F, Girodet J, Salmon RJ, Thomas G (1997) Alternative genetic pathways in colorectal carcinogenesis. Proc Natl Acad Sci USA 94: 12122-12127.
32. Overman MJ, Hu CY, Kopetz S, Abbruzzese JL, Wolff RA, Chang GJ (2012) A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease. Ann Surg Oncol 19: 1439-1445.
33. Overman MJ, Hu CY, Wolff RA, Chang GJ (2010a) Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database. Cancer 116: 5374-5382.
34. Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA (2010b) Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol 49: 474-479.
35. Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H (2010c) Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer 102: 144-150.
36. Palascak-Juif V, Bouvier AM, Cosnes J, Flourie B, Bouche O, Cadiot G, Lemann M, Bonaz B, Denet C, Marteau P, Gambiez L, Beaugerie L, Faivre J, Carbonnel F (2005) Small bowel adenocarcinoma in patients with Crohn's disease compared with small bowel adenocarcinoma de novo. Inflamm Bowel Dis 11: 828-832.
37. Park SJ, Rashid A, Lee JH, Kim SG, Hamilton SR, Wu TT (2003) Frequent CpG island methylation in serrated adenomas of the colorectum. Am J Pathol 162: 815-822.
38. Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R, Wiezorek J (2013) Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 31: 759-765.
39. Planck M, Ericson K, Piotrowska Z, Halvarsson B, Rambech E, Nilbert M (2003) Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine. Cancer 97: 1551-1557.
40. Samowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, Leppert MF, Slattery ML (2002) Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer 99: 597-602.
41. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S (2010) Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28: 3219-3226.
42. Svrcek M, Jourdan F, Sebbagh N, Couvelard A, Chatelain D, Mourra N, Olschwang S, Wendum D, Flejou JF (2003) Immunohistochemical analysis of adenocarcinoma of the small intestine: a tissue microarray study. J Clin Pathol 56: 898-903.
43. Talamonti MS, Goetz LH, Rao S, Joehl RJ (2002) Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg 137: 564-570.
44. Wheeler JM, Warren BF, Mortensen NJ, Kim HC, Biddolph SC, Elia G, Beck NE, Williams GT, Shepherd NA, Bateman AC, Bodmer WF (2002) An insight into the genetic pathway of adenocarcinoma of the small intestine. Gut 50: 218-223.
45. Younes N, Fulton N, Tanaka R, Wayne J, Straus FH, Kaplan EL (1997) The presence of K-12 ras mutations in duodenal adenocarcinomas and the absence of ras mutations in other small bowel adenocarcinomas and carcinoid tumors. Cancer 79: 1804-1808.
46. Zaanan A, Costes L, Gauthier M, Malka D, Locher C, Mitry E, Tougeron D, Lecomte T, Gornet JM, Sobhani I, Moulin V, Afchain P, Taieb J, Bonnetain F, Aparicio T (2010) Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol 21: 1786-1793.
47. Zaanan A, Gauthier M, Malka D, Locher C, Gornet JM, Thirot-Bidault A, Tougeron D, Taieb J, Bonnetain F, Aparicio T (2011a) Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. Cancer 117: 1422-1428.
48. Zaanan A, Meunier K, Sangar F, Flejou JF, Praz F (2011b) Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications. Cell Oncol (Dordr) 34: 155-176.
49. Zhang MQ, Chen ZM, Wang HL (2006) Immunohistochemical investigation of tumorigenic pathways in small intestinal adenocarcinoma: a comparison with colorectal adenocarcinoma. Mod Pathol 19: 573-580.
50. Zhu L, Kim K, Domenico DR, Appert HE, Howard JM (1996) Adenocarcinoma of duodenum and ampulla of Vater: clinicopathology study and expression of p53, c-neu, TGF-alpha, CEA, and EMA. J Surg Oncol 61: 100-105.